HUMACYTE, INC. (NASDAQ: HUMA) INVESTOR ALERT: Investors With Large Losses in Humacyte, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
Humacyte, Inc. (HUMA)
Company Research
Source: GlobeNewswire
NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, inclusive. For more information, submit a form at Humacyte, Inc. Shareholder Class Action Lawsuit, email Investor Relations Manager Peter Allocco at pallocco@bernlieb.com, or call us at (212) 951-2030. According to the lawsuit, Humacyte made misrepresentations concerning potential FDA approval of one of its products, the Acellular Tissue Engineered Vessel, relating to conditions at the Company’s Durham, North Carolina facility. If you wish to serve as lead plaintiff for the Class, you must file papers by January 17, 2025. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any rec
Show less
Read more
Impact Snapshot
Event Time:
HUMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HUMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HUMA alerts
High impacting Humacyte, Inc. news events
Weekly update
A roundup of the hottest topics
HUMA
News
- Humacyte and Pluristyx Announce Gene Editing Partnership to Support BioVascular Pancreas (BVP™) Development Using iPSCsGlobeNewswire
- https://seekingalpha.com/article/4751968-humacyte-upside-potential-i-will-wait-for-revenue-trends [Seeking Alpha]Seeking Alpha
- HUMACYTE ALERT: Bragar Eagel & Squire, P.C. is Investigating Humacyte, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmGlobeNewswire
- Humacyte, Inc. (NASDAQ: HUMA) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.MarketBeat
- Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV™ for Coronary Artery Bypass GraftingGlobeNewswire
HUMA
Earnings
- 11/8/24 - Miss
HUMA
Sec Filings
- 1/23/25 - Form 4
- 1/23/25 - Form 4
- 1/23/25 - Form 4
- HUMA's page on the SEC website